Use of cefoperazone in the empiric treatment of serious skin infections.
This report summarizes the results of a six-center clinical trial of cefoperazone as empiric therapy for hospitalized patients with serious infections of the skin and skin structures. Cefoperazone was administered in doses of 2-4 g once every 12 hr by iv infusion over 15-30 min or im injection. Results of therapy were evaluated for 39 of the 46 patients enrolled in the study. Of these 39 patients, 30 had a satisfactory clinical response to cefoperazone therapy, six had a partly satisfactory response, and three had an unsatisfactory response. A total of 78 pathogens were isolated from infected sites of the 39 patients, and MICs were determined for 62 of these pathogens. Of the 78 isolated pathogens, 63 (including five of eight isolates of Pseudomonas aeruginosa) were eradicated by cefoperazone. It is concluded that cefoperazone is a suitable antibiotic for empiric therapy for infections of the skin and skin structures of hospitalized patients.
D002438:Cefoperazone; D002511:Cephalosporins / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D012867:Skin / Q000473:pathology; D012874:Skin Diseases, Infectious / Q000188:drug therapy* / Q000382:microbiology / Q000473:pathology
D002511:Cephalosporins; D002438:Cefoperazone